119 related articles for article (PubMed ID: 8677161)
1. [Prognostic factors in neuroblastoma in children].
Izbicki T; Laskowska-Klita T; Liebhart M; Lipińska L
Pediatr Pol; 1995 Nov; 70(11):949-53. PubMed ID: 8677161
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma: biology, prognosis, and treatment.
Park JR; Eggert A; Caron H
Pediatr Clin North Am; 2008 Feb; 55(1):97-120, x. PubMed ID: 18242317
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma: biology, prognosis, and treatment.
Park JR; Eggert A; Caron H
Hematol Oncol Clin North Am; 2010 Feb; 24(1):65-86. PubMed ID: 20113896
[TBL] [Abstract][Full Text] [Related]
4. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
[TBL] [Abstract][Full Text] [Related]
5. Histopathological features of pretreatment neuroblastoma are of limited clinical significance following adjustment for clinical and biological marker status.
Sebire NJ
Med Hypotheses; 2006; 66(6):1078-81. PubMed ID: 16413685
[TBL] [Abstract][Full Text] [Related]
6. Predicting outcomes for children with neuroblastoma.
Vermeulen J; De Preter K; Mestdagh P; Laureys G; Speleman F; Vandesompele J
Discov Med; 2010 Jul; 10(50):29-36. PubMed ID: 20670596
[TBL] [Abstract][Full Text] [Related]
7. [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].
Pérel Y; Valteau-Couanet D; Michon J; Lavrand F; Coze C; Bergeron C; Notz A; Plantaz D; Chastagner P; Bernard F; Thomas C; Rubie H
Arch Pediatr; 2004 Jul; 11(7):834-42. PubMed ID: 15234382
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma.
Esiashvili N; Anderson C; Katzenstein HM
Curr Probl Cancer; 2009; 33(6):333-60. PubMed ID: 20172369
[No Abstract] [Full Text] [Related]
9. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
10. [Prognosis and prognostic factors in oncology and oncologic surgery ].
Gorbunov EA; Wechsler J
Vnitr Lek; 2004 Jan; 50(1):61-5. PubMed ID: 15015231
[TBL] [Abstract][Full Text] [Related]
11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
12. Pelvic neuroblastoma: low mortality and high morbidity.
Cruccetti A; Kiely EM; Spitz L; Drake DP; Pritchard J; Pierro A
J Pediatr Surg; 2000 May; 35(5):724-8. PubMed ID: 10813335
[TBL] [Abstract][Full Text] [Related]
13. Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry.
Ceschel S; Casotto V; Valsecchi MG; Tamaro P; Jankovic M; Hanau G; Fossati F; Pillon M; Rondelli R; Sandri A; Silvestri D; Haupt R; Cuttini M
Pediatr Blood Cancer; 2006 Oct; 47(5):560-6. PubMed ID: 16395684
[TBL] [Abstract][Full Text] [Related]
14. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
15. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
[TBL] [Abstract][Full Text] [Related]
17. Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group.
Sposto R; London WB; Alonzo TA;
J Clin Oncol; 2007 May; 25(15):2070-7. PubMed ID: 17513812
[TBL] [Abstract][Full Text] [Related]
18. [Management strategy in neuroblastoma].
Balwierz W
Przegl Lek; 2004; 61 Suppl 2():3-8. PubMed ID: 15686038
[TBL] [Abstract][Full Text] [Related]
19. [Advances in the diagnosis and treatment of neuroblastoma].
Kavan P; Koutecký J
Cas Lek Cesk; 1998 Apr; 137(8):231-6. PubMed ID: 9650346
[TBL] [Abstract][Full Text] [Related]
20. [The identification of minimal residual disease in the bone marrow and peripheral blood in neuroblastoma. The prognostic and therapeutic implications].
Faulkner LB; Tamburini A; Tintori V; Paoli A; Tondo A; Bernini G; Medicina D; Brisigotti M; Corrias MV; Scaruffi P; Rosanda C; Lo Piccolo MS; Viscardi E; Milanaccio C; Garaventa A; De Bernardi B
Pediatr Med Chir; 1998; 20(3):175-8. PubMed ID: 9744008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
